ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study

ATAI Life Sciences NV ATAI announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS).
Related Link: Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company.
Data demonstrated potential pro-cognitive effects of RL-007, a cholinergic, glutamatergic, and GABA type B receptor modulator.
After this early data, ATAI will commit additional financial resources for the accelerated development of RL-007.
The interim Phase 2a readout reported promising assessments from two quantitative biomarkers, qEEG (quantitative electroencephalogram) and ERP (evoked-response potential), and indicated changes consistent with improved cognition.
Full results of the current Phase 2a trial are expected by the end of 2021.
Related: Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial.
Price Action: ATAI shares closed 6.37% higher at $15.52 on Monday.